Karyopharm Therapeutics Inc. (KPTI) Stock Grade

About Karyopharm Therapeutics Inc.'s fundamentals

Karyopharm Therapeutics is a small-cap biotechnology company with a market capitalization of $36.7 million that reported minimal revenue growth of 0.6% year-over-year and a substantial net loss reflected in its negative net margin of -134.2%. The company does not currently pay a dividend and lacks a meaningful price-to-earnings ratio due to its unprofitability. Despite the operating losses, the company reported a return on equity of 66.9%, which may reflect volatility in shareholder equity rather than operational strength given the net loss position.